脂蛋白脂酶
高甘油三酯血症
医学
基因
遗传学
基因突变
突变
生物信息学
甘油三酯
内科学
生物
胆固醇
脂肪组织
作者
Rute Imanishi Rodrigues,Marta Artieda,Diego Tejedor,Antonio Martı́nez,Pavlina Konstantinova,Harald Petry,Christian Niels Meyer,Deyanira Corzo,Claus Sundgreen,Hans U. Klör,Ioanna Gouni‐Berthold,Sabine Westphal,Elisabeth Steinhagen‐Thiessen,Ulrich Julius,Karl Winkler,Erik S.G. Stroes,Anja Vogt,Phillip Hardt,Heinrich Prophet,Britta Otte
标识
DOI:10.1016/j.jacl.2015.12.015
摘要
Lipoprotein lipase (LPL) deficiency is a serious lipid disorder of severe hypertriglyceridemia (SHTG) with chylomicronemia. A large number of variants in the LPL gene have been reported but their influence on LPL activity and SHTG has not been completely analyzed. Gaining insight into the deleterious effect of the mutations is clinically essential.We used gene sequencing followed by in-vivo/in-vitro and in-silico tools for classification. We classified 125 rare LPL mutations in 33 subjects thought to have LPL deficiency and in 314 subjects selected for very SHTG.Of the 33 patients thought to have LPL deficiency, only 13 were homozygous or compound heterozygous for deleterious mutations in the LPL gene. Among the 314 very SHTG patients, 3 were compound heterozygous for pathogenic mutants. In a third group of 51,467 subjects, from a general population, carriers of common variants, Asp9Asn and Asn291Ser, were associated with mild increase in triglyceride levels (11%-35%).In total, 39% of patients clinically diagnosed as LPL deficient had 2 deleterious variants. Three patients selected for very SHTG had LPL deficiency. The deleterious mutations associated with LPL deficiency will assist in the diagnosis and selection of patients as candidates for the presently approved LPL gene therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI